ReviewWorld journal of emergency medicine2013
The Acinetobacter baumannii group: a systemic review.
Review in World journal of emergency medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Extensive screening of ten bacteriophage cocktails revealed an optimal combination with potent therapeutic activity against Acinetobacter baumannii.Scientific reports · 2026Article
- Sludge compost: a double-edged sword for depleted soil restoration revealed by integrated multi-omics analysis.Frontiers in microbiology · 2026Article
- In Vitro Antibacterial Efficacy of Recombinant Phage-Derived Endolysin LysTAC1 Against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- PCR-based RFLP and ERIC-PCR patterns of Helicobacter pylori strains linked to multidrug resistance in Egypt.Scientific reports · 2024Observational
- Characterization of antibiotic and disinfectant susceptibility in biofilm-forming Acinetobacter baumannii: A focus on environmental isolates.European journal of microbiology & immunology · 2024Article
- Phenotypical Comparison between Environmental and ClinicalThe Malaysian journal of medical sciences : MJMS · 2023Article
- Colistin Resistance inAntibiotics (Basel, Switzerland) · 2023Review
- Genetic Resistance Determinants in ClinicalAntibiotics (Basel, Switzerland) · 2022Article
- Acute Kidney Injury Among Patients with Multi-Drug Resistant Infection: A Study from Jordan.Journal of multidisciplinary healthcare · 2022Article
- Relationship between the Biofilm-Forming Capacity and Antimicrobial Resistance in ClinicalMicroorganisms · 2021Article
- Mapping Global Prevalence ofVaccines · 2021Review
- Polymyxin Resistance Among XDR ST1 Carbapenem-ResistantFrontiers in microbiology · 2021Article
- Detection of 5 Kinds of Genes Related to Plasmid-Mediated Quinolone Resistance in Four Species of Nonfermenting Bacteria with 2 Drug Resistant Phenotypes.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2020Article
- Detection of Antimicrobial Resistance Genes Associated with Carbapenem Resistance from the Whole-Genome Sequence ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2020Article
- Molecular Epidemiology of Emerging Carbapenem Resistance inAntimicrobial agents and chemotherapy · 2019Article
- Colistin Combined With Tigecycline: A Promising Alternative Strategy to CombatFrontiers in microbiology · 2019Article
- Draft Genome Sequences of Acinetobacter baumannii Strains Harboring the blaNDM-1 Gene Isolated in Lebanon from Civilians Wounded during the Syrian Civil War.Genome announcements · 2016Article
- Prevalence and Characterization of Integrons in Multidrug Resistant Acinetobacter baumannii in Eastern China: A Multiple-Hospital Study.International journal of environmental research and public health · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Acinetobacter baumannii group, including Acinetobacter baumannii, Acinetobacter genomospecies 3 and 13TU, is phenotypically indistinguishable and uniformly identified as Acinetobacter baumannii by laboratories of clinical microbiology. This review aimed to demonstrate the differences among them.
methodsLiteratures associated with the Acinetobacter baumannii group were identified and selected from PubMed databases and relevant journals.
resultsAcinetobacter genospecies 3 and 13TU possess a certain proportion in clinical isolates. There were considerable differences in epidemiologic features, clinical manifestations, antimicrobial resistances and therapeutic options among the Acinetobacter baumannii group. Compared with Acinetobacter genomospecies 3 and 13TU, Acinetobacter baumannii with a higher resistance to antimicrobial agents are easier to be treated inappropriately, and present a worse outcome in patients.
conclusionThe Acinetobacter baumannii group comprises three distinct clinical entities, and their clinical value are not equal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.